About the Authors

Gregory Penner

Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing

gpenner@neoneuro-aptamers.com

Affiliation NeoNeuro SAS, Villejuif, France

Soizic Lecocq

Roles Data curation, Formal analysis, Investigation, Resources, Software, Validation, Writing – original draft

Affiliation NeoNeuro SAS, Villejuif, France

Anaëlle Chopin

Roles Data curation, Formal analysis, Investigation, Resources, Software, Validation, Writing – original draft

Affiliation NeoNeuro SAS, Villejuif, France

Ximena Vedoya

Roles Funding acquisition, Project administration, Writing – review & editing

Affiliation NeoNeuro SAS, Villejuif, France

Simone Lista

Roles Resources, Writing – review & editing

Affiliations Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France, Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

Andrea Vergallo

Roles Resources, Writing – review & editing

Affiliation Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France

Enrica Cavedo

Roles Resources, Writing – review & editing

Affiliations Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France, Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Qynapse, Paris, France

Francois-Xavier Lejeune

Roles Formal analysis, Software, Writing – review & editing

Affiliation Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

Bruno Dubois

Roles Resources, Supervision, Writing – review & editing

Affiliations Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France, Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

Harald Hampel

Roles Resources, Supervision, Writing – review & editing

Affiliation Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France

the INSIGHT-preAD study group

a Membership of the INSIGHT-preAD study group membership listed in Acknowledgments.

for the Alzheimer Precision Medicine Initiative (APMI)

b Membership of the Alzheimer Precision Medicine Initiative (APMI) listed in Acknowledgments.

Competing Interests

GPenner received grant funding from GSK and has ownership over NeoNeuro. Gregory Penner has filed the following patents concerning work covered in this manuscript: “Aptamers as Biomarkers WO 2018/150030 A1” and “Early detection of precursor of Alzheimer’s disease WO 2020/079248 A1”. SLecocq and AChopin are employees of NeoNeuro. XVedoya has an ownership over NeoNeuro. SLista received lecture honoraria from Roche. AVergallo is an employee of Eisai Inc. He does not receive any fees or honoraria since November 2019. Before November 2019 he had he received lecture honoraria from Roche, MagQu LLC, and Servier. This work has been performed during his previous position at Sorbonne University, Paris, France. HHampel is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia and does not receive any fees or honoraria since May 2019; before May 2019 he had received lecture fees from Servier, Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE-Healthcare and Oryzon Genomics, consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. This work has been performed during his previous position at Sorbonne University, Paris, France. At Sorbonne University he was supported by the AXA Research Fund, the “Fondation partenariale Sorbonne Université” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. He is co-inventor in the following patents as a scientific expert and has received no royalties: • In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388 • In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784 • Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300 • In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463 • In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286 • In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822 • In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553 • CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797 • In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966 • Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921. This does not alter our adherence to PLOS ONE policies on sharing data and materials.